nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP3A4—Thiotepa—urinary bladder cancer	0.0493	0.23	CbGbCtD
Methazolamide—CYP2E1—Etoposide—urinary bladder cancer	0.0441	0.206	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—urinary bladder cancer	0.0331	0.154	CbGbCtD
Methazolamide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0276	0.129	CbGbCtD
Methazolamide—CYP2C9—Cisplatin—urinary bladder cancer	0.0234	0.109	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.0143	0.0669	CbGbCtD
Methazolamide—CYP3A4—Etoposide—urinary bladder cancer	0.0134	0.0624	CbGbCtD
Methazolamide—CYP2C19—urine—urinary bladder cancer	0.0122	0.0638	CbGeAlD
Methazolamide—CA14—prostate gland—urinary bladder cancer	0.01	0.0524	CbGeAlD
Methazolamide—CA5A—female reproductive system—urinary bladder cancer	0.00986	0.0517	CbGeAlD
Methazolamide—CYP2C9—urine—urinary bladder cancer	0.00944	0.0495	CbGeAlD
Methazolamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00912	0.0426	CbGbCtD
Methazolamide—CYP2E1—urine—urinary bladder cancer	0.00895	0.0469	CbGeAlD
Methazolamide—CA14—seminal vesicle—urinary bladder cancer	0.00846	0.0444	CbGeAlD
Methazolamide—CA7—renal system—urinary bladder cancer	0.00819	0.0429	CbGeAlD
Methazolamide—CYP3A4—urine—urinary bladder cancer	0.0072	0.0377	CbGeAlD
Methazolamide—CYP2D6—urine—urinary bladder cancer	0.00708	0.0371	CbGeAlD
Methazolamide—CA5B—prostate gland—urinary bladder cancer	0.007	0.0367	CbGeAlD
Methazolamide—CA9—female reproductive system—urinary bladder cancer	0.00576	0.0302	CbGeAlD
Methazolamide—CA12—renal system—urinary bladder cancer	0.00532	0.0279	CbGeAlD
Methazolamide—CA4—prostate gland—urinary bladder cancer	0.00483	0.0253	CbGeAlD
Methazolamide—CA5B—urethra—urinary bladder cancer	0.00469	0.0246	CbGeAlD
Methazolamide—CA12—female reproductive system—urinary bladder cancer	0.00426	0.0223	CbGeAlD
Methazolamide—CA1—renal system—urinary bladder cancer	0.00421	0.0221	CbGeAlD
Methazolamide—CA4—seminal vesicle—urinary bladder cancer	0.00409	0.0214	CbGeAlD
Methazolamide—CA2—prostate gland—urinary bladder cancer	0.00401	0.021	CbGeAlD
Methazolamide—CA5B—female reproductive system—urinary bladder cancer	0.00382	0.02	CbGeAlD
Methazolamide—CA5B—vagina—urinary bladder cancer	0.00346	0.0181	CbGeAlD
Methazolamide—CA2—seminal vesicle—urinary bladder cancer	0.00339	0.0178	CbGeAlD
Methazolamide—CA1—female reproductive system—urinary bladder cancer	0.00337	0.0177	CbGeAlD
Methazolamide—CA4—renal system—urinary bladder cancer	0.00329	0.0173	CbGeAlD
Methazolamide—CA4—urethra—urinary bladder cancer	0.00323	0.017	CbGeAlD
Methazolamide—CYP2E1—prostate gland—urinary bladder cancer	0.00321	0.0168	CbGeAlD
Methazolamide—CA2—epithelium—urinary bladder cancer	0.00294	0.0154	CbGeAlD
Methazolamide—CA2—smooth muscle tissue—urinary bladder cancer	0.00284	0.0149	CbGeAlD
Methazolamide—CA2—renal system—urinary bladder cancer	0.00273	0.0143	CbGeAlD
Methazolamide—CYP2E1—seminal vesicle—urinary bladder cancer	0.00272	0.0142	CbGeAlD
Methazolamide—CA4—female reproductive system—urinary bladder cancer	0.00264	0.0138	CbGeAlD
Methazolamide—CA5B—lymph node—urinary bladder cancer	0.00224	0.0117	CbGeAlD
Methazolamide—CYP2E1—renal system—urinary bladder cancer	0.00219	0.0115	CbGeAlD
Methazolamide—CA2—female reproductive system—urinary bladder cancer	0.00219	0.0115	CbGeAlD
Methazolamide—CYP2C19—vagina—urinary bladder cancer	0.00216	0.0113	CbGeAlD
Methazolamide—CYP2E1—urethra—urinary bladder cancer	0.00215	0.0113	CbGeAlD
Methazolamide—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00198	0.00536	CcSEcCtD
Methazolamide—CA2—vagina—urinary bladder cancer	0.00198	0.0104	CbGeAlD
Methazolamide—CA1—lymph node—urinary bladder cancer	0.00197	0.0103	CbGeAlD
Methazolamide—Asthenia—Mitomycin—urinary bladder cancer	0.00193	0.00522	CcSEcCtD
Methazolamide—Pancytopenia—Gemcitabine—urinary bladder cancer	0.0019	0.00514	CcSEcCtD
Methazolamide—Glycosuria—Epirubicin—urinary bladder cancer	0.00189	0.0051	CcSEcCtD
Methazolamide—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00187	0.00506	CcSEcCtD
Methazolamide—CYP2C9—female reproductive system—urinary bladder cancer	0.00185	0.0097	CbGeAlD
Methazolamide—Diarrhoea—Mitomycin—urinary bladder cancer	0.00184	0.00498	CcSEcCtD
Methazolamide—Blood disorder—Epirubicin—urinary bladder cancer	0.00183	0.00495	CcSEcCtD
Methazolamide—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.0018	0.00486	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00178	0.00482	CcSEcCtD
Methazolamide—Tinnitus—Thiotepa—urinary bladder cancer	0.00178	0.00481	CcSEcCtD
Methazolamide—Pancytopenia—Cisplatin—urinary bladder cancer	0.00177	0.00479	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00177	0.00479	CcSEcCtD
Methazolamide—CYP3A4—renal system—urinary bladder cancer	0.00176	0.00923	CbGeAlD
Methazolamide—CYP2E1—female reproductive system—urinary bladder cancer	0.00175	0.00919	CbGeAlD
Methazolamide—Glycosuria—Doxorubicin—urinary bladder cancer	0.00175	0.00472	CcSEcCtD
Methazolamide—CYP2D6—renal system—urinary bladder cancer	0.00173	0.00909	CbGeAlD
Methazolamide—Vomiting—Mitomycin—urinary bladder cancer	0.00171	0.00463	CcSEcCtD
Methazolamide—Haematuria—Gemcitabine—urinary bladder cancer	0.0017	0.0046	CcSEcCtD
Methazolamide—Rash—Mitomycin—urinary bladder cancer	0.0017	0.00459	CcSEcCtD
Methazolamide—Dermatitis—Mitomycin—urinary bladder cancer	0.0017	0.00459	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—urinary bladder cancer	0.00169	0.00458	CcSEcCtD
Methazolamide—Headache—Mitomycin—urinary bladder cancer	0.00169	0.00456	CcSEcCtD
Methazolamide—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00167	0.00451	CcSEcCtD
Methazolamide—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00164	0.00443	CcSEcCtD
Methazolamide—Pancytopenia—Etoposide—urinary bladder cancer	0.00162	0.00439	CcSEcCtD
Methazolamide—Nausea—Mitomycin—urinary bladder cancer	0.0016	0.00432	CcSEcCtD
Methazolamide—Melaena—Methotrexate—urinary bladder cancer	0.0016	0.00431	CcSEcCtD
Methazolamide—CA4—lymph node—urinary bladder cancer	0.00154	0.00809	CbGeAlD
Methazolamide—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00153	0.00415	CcSEcCtD
Methazolamide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00152	0.0041	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00151	0.00409	CcSEcCtD
Methazolamide—Melaena—Epirubicin—urinary bladder cancer	0.00149	0.00404	CcSEcCtD
Methazolamide—Leukopenia—Thiotepa—urinary bladder cancer	0.00149	0.00402	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—urinary bladder cancer	0.00148	0.00399	CcSEcCtD
Methazolamide—Convulsion—Thiotepa—urinary bladder cancer	0.00144	0.00389	CcSEcCtD
Methazolamide—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00144	0.00388	CcSEcCtD
Methazolamide—Agranulocytosis—Etoposide—urinary bladder cancer	0.00142	0.00385	CcSEcCtD
Methazolamide—CYP3A4—female reproductive system—urinary bladder cancer	0.00141	0.0074	CbGeAlD
Methazolamide—Tinnitus—Cisplatin—urinary bladder cancer	0.00139	0.00377	CcSEcCtD
Methazolamide—CYP2D6—female reproductive system—urinary bladder cancer	0.00139	0.00728	CbGeAlD
Methazolamide—Melaena—Doxorubicin—urinary bladder cancer	0.00138	0.00374	CcSEcCtD
Methazolamide—Confusional state—Thiotepa—urinary bladder cancer	0.00137	0.00369	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—urinary bladder cancer	0.00135	0.00365	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—urinary bladder cancer	0.00135	0.00365	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00133	0.00359	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—urinary bladder cancer	0.00132	0.00357	CcSEcCtD
Methazolamide—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.0013	0.0035	CcSEcCtD
Methazolamide—Erythema multiforme—Etoposide—urinary bladder cancer	0.00129	0.0035	CcSEcCtD
Methazolamide—Anorexia—Thiotepa—urinary bladder cancer	0.00129	0.00349	CcSEcCtD
Methazolamide—CA2—lymph node—urinary bladder cancer	0.00128	0.00671	CbGeAlD
Methazolamide—Photosensitivity—Epirubicin—urinary bladder cancer	0.00126	0.00342	CcSEcCtD
Methazolamide—Malaise—Gemcitabine—urinary bladder cancer	0.00126	0.0034	CcSEcCtD
Methazolamide—Leukopenia—Gemcitabine—urinary bladder cancer	0.00125	0.00338	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—urinary bladder cancer	0.00123	0.00334	CcSEcCtD
Methazolamide—Leukopenia—Fluorouracil—urinary bladder cancer	0.00123	0.00332	CcSEcCtD
Methazolamide—Paraesthesia—Thiotepa—urinary bladder cancer	0.00122	0.00329	CcSEcCtD
Methazolamide—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00121	0.00326	CcSEcCtD
Methazolamide—Somnolence—Thiotepa—urinary bladder cancer	0.0012	0.00326	CcSEcCtD
Methazolamide—Dyspepsia—Thiotepa—urinary bladder cancer	0.00119	0.00322	CcSEcCtD
Methazolamide—Convulsion—Fluorouracil—urinary bladder cancer	0.00119	0.00322	CcSEcCtD
Methazolamide—Decreased appetite—Thiotepa—urinary bladder cancer	0.00118	0.00318	CcSEcCtD
Methazolamide—Discomfort—Gemcitabine—urinary bladder cancer	0.00117	0.00317	CcSEcCtD
Methazolamide—Malaise—Cisplatin—urinary bladder cancer	0.00117	0.00317	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00117	0.00316	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—urinary bladder cancer	0.00117	0.00316	CcSEcCtD
Methazolamide—Fatigue—Thiotepa—urinary bladder cancer	0.00117	0.00316	CcSEcCtD
Methazolamide—Dysgeusia—Etoposide—urinary bladder cancer	0.00117	0.00316	CcSEcCtD
Methazolamide—Leukopenia—Cisplatin—urinary bladder cancer	0.00116	0.00315	CcSEcCtD
Methazolamide—Discomfort—Fluorouracil—urinary bladder cancer	0.00115	0.00312	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—urinary bladder cancer	0.00114	0.00309	CcSEcCtD
Methazolamide—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00114	0.00308	CcSEcCtD
Methazolamide—Confusional state—Fluorouracil—urinary bladder cancer	0.00113	0.00305	CcSEcCtD
Methazolamide—Convulsion—Cisplatin—urinary bladder cancer	0.00113	0.00305	CcSEcCtD
Methazolamide—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00112	0.00303	CcSEcCtD
Methazolamide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00112	0.00302	CcSEcCtD
Methazolamide—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00111	0.00299	CcSEcCtD
Methazolamide—Discomfort—Cisplatin—urinary bladder cancer	0.00109	0.00296	CcSEcCtD
Methazolamide—Anorexia—Gemcitabine—urinary bladder cancer	0.00109	0.00294	CcSEcCtD
Methazolamide—Urticaria—Thiotepa—urinary bladder cancer	0.00108	0.00291	CcSEcCtD
Methazolamide—Malaise—Etoposide—urinary bladder cancer	0.00108	0.00291	CcSEcCtD
Methazolamide—Vertigo—Etoposide—urinary bladder cancer	0.00107	0.0029	CcSEcCtD
Methazolamide—Body temperature increased—Thiotepa—urinary bladder cancer	0.00107	0.00289	CcSEcCtD
Methazolamide—Anorexia—Fluorouracil—urinary bladder cancer	0.00107	0.00289	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00107	0.00289	CcSEcCtD
Methazolamide—Leukopenia—Etoposide—urinary bladder cancer	0.00107	0.00288	CcSEcCtD
Methazolamide—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00106	0.00287	CcSEcCtD
Methazolamide—Convulsion—Etoposide—urinary bladder cancer	0.00103	0.00279	CcSEcCtD
Methazolamide—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00102	0.00277	CcSEcCtD
Methazolamide—Somnolence—Gemcitabine—urinary bladder cancer	0.00101	0.00274	CcSEcCtD
Methazolamide—Anorexia—Cisplatin—urinary bladder cancer	0.00101	0.00274	CcSEcCtD
Methazolamide—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00101	0.00272	CcSEcCtD
Methazolamide—Discomfort—Etoposide—urinary bladder cancer	0.001	0.00271	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000999	0.0027	CcSEcCtD
Methazolamide—Somnolence—Fluorouracil—urinary bladder cancer	0.000996	0.00269	CcSEcCtD
Methazolamide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00099	0.00268	CcSEcCtD
Methazolamide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000986	0.00267	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000984	0.00266	CcSEcCtD
Methazolamide—Fatigue—Gemcitabine—urinary bladder cancer	0.000982	0.00266	CcSEcCtD
Methazolamide—Confusional state—Etoposide—urinary bladder cancer	0.000981	0.00265	CcSEcCtD
Methazolamide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000974	0.00263	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—urinary bladder cancer	0.000973	0.00263	CcSEcCtD
Methazolamide—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000973	0.00263	CcSEcCtD
Methazolamide—Asthenia—Thiotepa—urinary bladder cancer	0.000972	0.00263	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000967	0.00261	CcSEcCtD
Methazolamide—Paraesthesia—Cisplatin—urinary bladder cancer	0.000954	0.00258	CcSEcCtD
Methazolamide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000939	0.00254	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000935	0.00253	CcSEcCtD
Methazolamide—Anorexia—Etoposide—urinary bladder cancer	0.000927	0.00251	CcSEcCtD
Methazolamide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000927	0.00251	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000925	0.0025	CcSEcCtD
Methazolamide—Decreased appetite—Cisplatin—urinary bladder cancer	0.000923	0.0025	CcSEcCtD
Methazolamide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000923	0.0025	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000917	0.00248	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—urinary bladder cancer	0.000914	0.00247	CcSEcCtD
Methazolamide—Pancytopenia—Epirubicin—urinary bladder cancer	0.000911	0.00246	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000906	0.00245	CcSEcCtD
Methazolamide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000901	0.00244	CcSEcCtD
Methazolamide—Urticaria—Fluorouracil—urinary bladder cancer	0.00089	0.00241	CcSEcCtD
Methazolamide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000886	0.00239	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000875	0.00237	CcSEcCtD
Methazolamide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000875	0.00237	CcSEcCtD
Methazolamide—Paraesthesia—Etoposide—urinary bladder cancer	0.000874	0.00236	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—urinary bladder cancer	0.000871	0.00236	CcSEcCtD
Methazolamide—Somnolence—Etoposide—urinary bladder cancer	0.000865	0.00234	CcSEcCtD
Methazolamide—Vomiting—Thiotepa—urinary bladder cancer	0.000861	0.00233	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—urinary bladder cancer	0.000855	0.00231	CcSEcCtD
Methazolamide—Rash—Thiotepa—urinary bladder cancer	0.000854	0.00231	CcSEcCtD
Methazolamide—Dermatitis—Thiotepa—urinary bladder cancer	0.000853	0.00231	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000853	0.00231	CcSEcCtD
Methazolamide—Headache—Thiotepa—urinary bladder cancer	0.000848	0.00229	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000848	0.00229	CcSEcCtD
Methazolamide—Decreased appetite—Etoposide—urinary bladder cancer	0.000846	0.00229	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000843	0.00228	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00084	0.00227	CcSEcCtD
Methazolamide—Body temperature increased—Cisplatin—urinary bladder cancer	0.00084	0.00227	CcSEcCtD
Methazolamide—Fatigue—Etoposide—urinary bladder cancer	0.000839	0.00227	CcSEcCtD
Methazolamide—Asthenia—Gemcitabine—urinary bladder cancer	0.000817	0.00221	CcSEcCtD
Methazolamide—Haematuria—Epirubicin—urinary bladder cancer	0.000815	0.0022	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00081	0.00219	CcSEcCtD
Methazolamide—Nausea—Thiotepa—urinary bladder cancer	0.000805	0.00217	CcSEcCtD
Methazolamide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000802	0.00217	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000798	0.00216	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—urinary bladder cancer	0.000791	0.00214	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000784	0.00212	CcSEcCtD
Methazolamide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00078	0.00211	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000776	0.0021	CcSEcCtD
Methazolamide—Urticaria—Etoposide—urinary bladder cancer	0.000773	0.00209	CcSEcCtD
Methazolamide—Body temperature increased—Etoposide—urinary bladder cancer	0.000769	0.00208	CcSEcCtD
Methazolamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000766	0.00207	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—urinary bladder cancer	0.000765	0.00207	CcSEcCtD
Methazolamide—Asthenia—Cisplatin—urinary bladder cancer	0.000762	0.00206	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—urinary bladder cancer	0.000754	0.00204	CcSEcCtD
Methazolamide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000738	0.002	CcSEcCtD
Methazolamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000727	0.00196	CcSEcCtD
Methazolamide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000726	0.00196	CcSEcCtD
Methazolamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000724	0.00196	CcSEcCtD
Methazolamide—Rash—Gemcitabine—urinary bladder cancer	0.000718	0.00194	CcSEcCtD
Methazolamide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000718	0.00194	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—urinary bladder cancer	0.000716	0.00193	CcSEcCtD
Methazolamide—Headache—Gemcitabine—urinary bladder cancer	0.000714	0.00193	CcSEcCtD
Methazolamide—Vomiting—Fluorouracil—urinary bladder cancer	0.000712	0.00193	CcSEcCtD
Methazolamide—Rash—Fluorouracil—urinary bladder cancer	0.000706	0.00191	CcSEcCtD
Methazolamide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000706	0.00191	CcSEcCtD
Methazolamide—Headache—Fluorouracil—urinary bladder cancer	0.000702	0.0019	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000699	0.00189	CcSEcCtD
Methazolamide—Asthenia—Etoposide—urinary bladder cancer	0.000698	0.00189	CcSEcCtD
Methazolamide—Nausea—Gemcitabine—urinary bladder cancer	0.000677	0.00183	CcSEcCtD
Methazolamide—Vomiting—Cisplatin—urinary bladder cancer	0.000675	0.00183	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000672	0.00182	CcSEcCtD
Methazolamide—Rash—Cisplatin—urinary bladder cancer	0.00067	0.00181	CcSEcCtD
Methazolamide—Dermatitis—Cisplatin—urinary bladder cancer	0.000669	0.00181	CcSEcCtD
Methazolamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000666	0.0018	CcSEcCtD
Methazolamide—Nausea—Fluorouracil—urinary bladder cancer	0.000665	0.0018	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000663	0.00179	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000662	0.00179	CcSEcCtD
Methazolamide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000654	0.00177	CcSEcCtD
Methazolamide—Malaise—Methotrexate—urinary bladder cancer	0.000644	0.00174	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—urinary bladder cancer	0.000642	0.00173	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—urinary bladder cancer	0.000639	0.00173	CcSEcCtD
Methazolamide—Nausea—Cisplatin—urinary bladder cancer	0.000631	0.00171	CcSEcCtD
Methazolamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00062	0.00168	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—urinary bladder cancer	0.000619	0.00167	CcSEcCtD
Methazolamide—Vomiting—Etoposide—urinary bladder cancer	0.000619	0.00167	CcSEcCtD
Methazolamide—Rash—Etoposide—urinary bladder cancer	0.000613	0.00166	CcSEcCtD
Methazolamide—Dermatitis—Etoposide—urinary bladder cancer	0.000613	0.00166	CcSEcCtD
Methazolamide—Headache—Etoposide—urinary bladder cancer	0.000609	0.00165	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000605	0.00164	CcSEcCtD
Methazolamide—Malaise—Epirubicin—urinary bladder cancer	0.000603	0.00163	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—urinary bladder cancer	0.000601	0.00162	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—urinary bladder cancer	0.0006	0.00162	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—urinary bladder cancer	0.000598	0.00162	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—urinary bladder cancer	0.000588	0.00159	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000583	0.00158	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—urinary bladder cancer	0.000579	0.00157	CcSEcCtD
Methazolamide—Nausea—Etoposide—urinary bladder cancer	0.000578	0.00156	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000574	0.00155	CcSEcCtD
Methazolamide—Discomfort—Epirubicin—urinary bladder cancer	0.000562	0.00152	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—urinary bladder cancer	0.000558	0.00151	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—urinary bladder cancer	0.000555	0.0015	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—urinary bladder cancer	0.000555	0.0015	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000553	0.0015	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—urinary bladder cancer	0.00055	0.00149	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000545	0.00147	CcSEcCtD
Methazolamide—Convulsion—Doxorubicin—urinary bladder cancer	0.000536	0.00145	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000523	0.00141	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—urinary bladder cancer	0.00052	0.00141	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—urinary bladder cancer	0.00052	0.00141	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—urinary bladder cancer	0.000518	0.0014	CcSEcCtD
Methazolamide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000513	0.00139	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—urinary bladder cancer	0.000509	0.00138	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000507	0.00137	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000505	0.00136	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000503	0.00136	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—urinary bladder cancer	0.000502	0.00136	CcSEcCtD
Methazolamide—Paraesthesia—Epirubicin—urinary bladder cancer	0.00049	0.00132	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—urinary bladder cancer	0.000485	0.00131	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—urinary bladder cancer	0.000481	0.0013	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00048	0.0013	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—urinary bladder cancer	0.00048	0.0013	CcSEcCtD
Methazolamide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000474	0.00128	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000471	0.00127	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—urinary bladder cancer	0.00047	0.00127	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—urinary bladder cancer	0.000463	0.00125	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000461	0.00125	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000453	0.00122	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000449	0.00121	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—urinary bladder cancer	0.000449	0.00121	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000444	0.0012	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000439	0.00119	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000436	0.00118	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—urinary bladder cancer	0.000435	0.00118	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—urinary bladder cancer	0.000433	0.00117	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000431	0.00117	CcSEcCtD
Methazolamide—Asthenia—Methotrexate—urinary bladder cancer	0.000418	0.00113	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000416	0.00112	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000401	0.00108	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000399	0.00108	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000399	0.00108	CcSEcCtD
Methazolamide—Asthenia—Epirubicin—urinary bladder cancer	0.000391	0.00106	CcSEcCtD
Methazolamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000373	0.00101	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—urinary bladder cancer	0.000371	0.001	CcSEcCtD
Methazolamide—Rash—Methotrexate—urinary bladder cancer	0.000367	0.000993	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—urinary bladder cancer	0.000367	0.000992	CcSEcCtD
Methazolamide—Headache—Methotrexate—urinary bladder cancer	0.000365	0.000987	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000362	0.000979	CcSEcCtD
Methazolamide—Vomiting—Epirubicin—urinary bladder cancer	0.000347	0.000937	CcSEcCtD
Methazolamide—Nausea—Methotrexate—urinary bladder cancer	0.000346	0.000936	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000345	0.000933	CcSEcCtD
Methazolamide—Rash—Epirubicin—urinary bladder cancer	0.000344	0.00093	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—urinary bladder cancer	0.000344	0.000929	CcSEcCtD
Methazolamide—Headache—Epirubicin—urinary bladder cancer	0.000342	0.000924	CcSEcCtD
Methazolamide—Nausea—Epirubicin—urinary bladder cancer	0.000324	0.000876	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—urinary bladder cancer	0.000321	0.000867	CcSEcCtD
Methazolamide—Rash—Doxorubicin—urinary bladder cancer	0.000318	0.00086	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000318	0.000859	CcSEcCtD
Methazolamide—Headache—Doxorubicin—urinary bladder cancer	0.000316	0.000855	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—urinary bladder cancer	0.0003	0.00081	CcSEcCtD
Methazolamide—CA6—Metabolism—MTHFR—urinary bladder cancer	0.000148	0.000659	CbGpPWpGaD
Methazolamide—CA7—Metabolism—ERCC2—urinary bladder cancer	0.000147	0.000655	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—ERCC2—urinary bladder cancer	0.000147	0.000655	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTT1—urinary bladder cancer	0.000147	0.000653	CbGpPWpGaD
Methazolamide—CA12—Metabolism—TYMS—urinary bladder cancer	0.000147	0.000653	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GSTM1—urinary bladder cancer	0.000145	0.000645	CbGpPWpGaD
Methazolamide—CA12—Metabolism—NCOR1—urinary bladder cancer	0.000145	0.000645	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NQO1—urinary bladder cancer	0.000145	0.000644	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000145	0.000643	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000141	0.000626	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.00014	0.000621	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GPX1—urinary bladder cancer	0.000139	0.000618	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000139	0.000618	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NQO1—urinary bladder cancer	0.000139	0.000617	CbGpPWpGaD
Methazolamide—CA7—Metabolism—MTHFR—urinary bladder cancer	0.000139	0.000616	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—MTHFR—urinary bladder cancer	0.000139	0.000616	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000138	0.000612	CbGpPWpGaD
Methazolamide—CA12—Metabolism—ERCC2—urinary bladder cancer	0.000137	0.000607	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	0.000132	0.000588	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—urinary bladder cancer	0.00013	0.000579	CbGpPWpGaD
Methazolamide—CA12—Metabolism—MTHFR—urinary bladder cancer	0.000128	0.00057	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GSTP1—urinary bladder cancer	0.000126	0.00056	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	0.000125	0.000558	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NAT1—urinary bladder cancer	0.000125	0.000558	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PPARG—urinary bladder cancer	0.000123	0.000549	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NQO1—urinary bladder cancer	0.000122	0.000543	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GSTP1—urinary bladder cancer	0.000121	0.000537	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PPARG—urinary bladder cancer	0.00012	0.000535	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PPARG—urinary bladder cancer	0.00012	0.000535	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CREBBP—urinary bladder cancer	0.000119	0.000527	CbGpPWpGaD
Methazolamide—CA4—Metabolism—TYMS—urinary bladder cancer	0.000117	0.000521	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTP1—urinary bladder cancer	0.000116	0.000515	CbGpPWpGaD
Methazolamide—CA4—Metabolism—NCOR1—urinary bladder cancer	0.000116	0.000515	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GSTM1—urinary bladder cancer	0.000116	0.000515	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CREBBP—urinary bladder cancer	0.000116	0.000514	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CREBBP—urinary bladder cancer	0.000116	0.000514	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	0.000115	0.00051	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PPARG—urinary bladder cancer	0.000112	0.000499	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PPARG—urinary bladder cancer	0.000112	0.000499	CbGpPWpGaD
Methazolamide—CA2—Metabolism—TYMS—urinary bladder cancer	0.000112	0.000499	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GSTM1—urinary bladder cancer	0.000111	0.000493	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NCOR1—urinary bladder cancer	0.000111	0.000493	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GPX1—urinary bladder cancer	0.000111	0.000493	CbGpPWpGaD
Methazolamide—CA4—Metabolism—ERCC2—urinary bladder cancer	0.000109	0.000484	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CREBBP—urinary bladder cancer	0.000108	0.00048	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CREBBP—urinary bladder cancer	0.000108	0.00048	CbGpPWpGaD
Methazolamide—CA1—Metabolism—TYMS—urinary bladder cancer	0.000108	0.000479	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTM1—urinary bladder cancer	0.000106	0.000473	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NCOR1—urinary bladder cancer	0.000106	0.000473	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GPX1—urinary bladder cancer	0.000106	0.000472	CbGpPWpGaD
Methazolamide—CA2—Metabolism—ERCC2—urinary bladder cancer	0.000104	0.000464	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PPARG—urinary bladder cancer	0.000104	0.000462	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	0.000103	0.000459	CbGpPWpGaD
Methazolamide—CA4—Metabolism—MTHFR—urinary bladder cancer	0.000102	0.000455	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000102	0.000454	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GPX1—urinary bladder cancer	0.000102	0.000453	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTP1—urinary bladder cancer	0.000102	0.000453	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.0001	0.000445	CbGpPWpGaD
Methazolamide—CA1—Metabolism—ERCC2—urinary bladder cancer	0.0001	0.000445	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CREBBP—urinary bladder cancer	0.0001	0.000444	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.89e-05	0.000439	CbGpPWpGaD
Methazolamide—CA2—Metabolism—MTHFR—urinary bladder cancer	9.81e-05	0.000436	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	9.76e-05	0.000434	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTGS2—urinary bladder cancer	9.71e-05	0.000432	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	9.68e-05	0.00043	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	9.68e-05	0.00043	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.52e-05	0.000423	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	9.51e-05	0.000423	CbGpPWpGaD
Methazolamide—CA9—Metabolism—TYMS—urinary bladder cancer	9.47e-05	0.000421	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTGS2—urinary bladder cancer	9.47e-05	0.000421	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTGS2—urinary bladder cancer	9.47e-05	0.000421	CbGpPWpGaD
Methazolamide—CA1—Metabolism—MTHFR—urinary bladder cancer	9.41e-05	0.000418	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	9.39e-05	0.000417	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTM1—urinary bladder cancer	9.36e-05	0.000416	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NCOR1—urinary bladder cancer	9.36e-05	0.000416	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	9.31e-05	0.000414	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	9.21e-05	0.000409	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.08e-05	0.000404	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GPX1—urinary bladder cancer	8.96e-05	0.000398	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.9e-05	0.000396	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.9e-05	0.000396	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	8.85e-05	0.000393	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTGS2—urinary bladder cancer	8.84e-05	0.000393	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTGS2—urinary bladder cancer	8.84e-05	0.000393	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	8.83e-05	0.000392	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	8.83e-05	0.000392	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ERCC2—urinary bladder cancer	8.8e-05	0.000391	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.68e-05	0.000386	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTEN—urinary bladder cancer	8.47e-05	0.000376	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PPARG—urinary bladder cancer	8.3e-05	0.000369	CbGpPWpGaD
Methazolamide—CA9—Metabolism—MTHFR—urinary bladder cancer	8.27e-05	0.000368	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTEN—urinary bladder cancer	8.25e-05	0.000367	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTEN—urinary bladder cancer	8.25e-05	0.000367	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.25e-05	0.000367	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTGS2—urinary bladder cancer	8.19e-05	0.000364	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	8.14e-05	0.000362	CbGpPWpGaD
Methazolamide—CA14—Metabolism—EP300—urinary bladder cancer	8.08e-05	0.000359	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	8.07e-05	0.000359	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CREBBP—urinary bladder cancer	7.97e-05	0.000354	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	7.97e-05	0.000354	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PPARG—urinary bladder cancer	7.96e-05	0.000354	CbGpPWpGaD
Methazolamide—CA6—Metabolism—EP300—urinary bladder cancer	7.87e-05	0.00035	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—EP300—urinary bladder cancer	7.87e-05	0.00035	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTEN—urinary bladder cancer	7.71e-05	0.000342	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTEN—urinary bladder cancer	7.71e-05	0.000342	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CREBBP—urinary bladder cancer	7.64e-05	0.00034	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PPARG—urinary bladder cancer	7.63e-05	0.000339	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—TYMP—urinary bladder cancer	7.6e-05	0.000338	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	7.53e-05	0.000335	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—EP300—urinary bladder cancer	7.35e-05	0.000327	CbGpPWpGaD
Methazolamide—CA7—Metabolism—EP300—urinary bladder cancer	7.35e-05	0.000327	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	7.34e-05	0.000326	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	7.33e-05	0.000326	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CREBBP—urinary bladder cancer	7.33e-05	0.000326	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	7.27e-05	0.000323	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTEN—urinary bladder cancer	7.14e-05	0.000317	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.92e-05	0.000308	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NAT2—urinary bladder cancer	6.87e-05	0.000306	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.86e-05	0.000305	CbGpPWpGaD
Methazolamide—CA12—Metabolism—EP300—urinary bladder cancer	6.81e-05	0.000303	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.75e-05	0.0003	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PPARG—urinary bladder cancer	6.71e-05	0.000298	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.69e-05	0.000297	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—urinary bladder cancer	6.53e-05	0.00029	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CREBBP—urinary bladder cancer	6.44e-05	0.000286	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—urinary bladder cancer	6.26e-05	0.000278	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.14e-05	0.000273	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—urinary bladder cancer	6e-05	0.000267	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—RRM2—urinary bladder cancer	5.93e-05	0.000264	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.88e-05	0.000261	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	5.86e-05	0.000261	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.82e-05	0.000259	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.82e-05	0.000259	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTEN—urinary bladder cancer	5.69e-05	0.000253	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.63e-05	0.00025	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	5.5e-05	0.000244	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ENO2—urinary bladder cancer	5.5e-05	0.000244	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTEN—urinary bladder cancer	5.46e-05	0.000243	CbGpPWpGaD
Methazolamide—CA4—Metabolism—EP300—urinary bladder cancer	5.43e-05	0.000241	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.39e-05	0.00024	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.36e-05	0.000238	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.35e-05	0.000238	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	5.33e-05	0.000237	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.32e-05	0.000237	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	5.3e-05	0.000236	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—urinary bladder cancer	5.28e-05	0.000234	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTEN—urinary bladder cancer	5.23e-05	0.000233	CbGpPWpGaD
Methazolamide—CA2—Metabolism—EP300—urinary bladder cancer	5.21e-05	0.000231	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.14e-05	0.000228	CbGpPWpGaD
Methazolamide—CA1—Metabolism—EP300—urinary bladder cancer	4.99e-05	0.000222	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.88e-05	0.000217	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.84e-05	0.000215	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.79e-05	0.000213	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTEN—urinary bladder cancer	4.6e-05	0.000204	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.58e-05	0.000203	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.53e-05	0.000201	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NQO1—urinary bladder cancer	4.43e-05	0.000197	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.41e-05	0.000196	CbGpPWpGaD
Methazolamide—CA9—Metabolism—EP300—urinary bladder cancer	4.39e-05	0.000195	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.24e-05	0.000188	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.24e-05	0.000188	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.22e-05	0.000187	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.21e-05	0.000187	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.17e-05	0.000186	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.11e-05	0.000183	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.05e-05	0.00018	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.9e-05	0.000173	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.9e-05	0.000173	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.87e-05	0.000172	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.87e-05	0.000172	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.84e-05	0.000171	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.78e-05	0.000168	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.75e-05	0.000167	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	3.69e-05	0.000164	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.69e-05	0.000164	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.53e-05	0.000157	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—TYMS—urinary bladder cancer	3.43e-05	0.000153	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.42e-05	0.000152	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	3.4e-05	0.000151	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	3.4e-05	0.000151	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.32e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GPX1—urinary bladder cancer	3.25e-05	0.000144	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	3.19e-05	0.000142	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.19e-05	0.000142	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.14e-05	0.00014	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.12e-05	0.000138	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.02e-05	0.000134	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	3e-05	0.000133	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.89e-05	0.000129	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.85e-05	0.000127	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.76e-05	0.000123	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.75e-05	0.000122	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.65e-05	0.000118	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.64e-05	0.000117	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.62e-05	0.000117	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.62e-05	0.000116	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.62e-05	0.000116	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.6e-05	0.000116	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.55e-05	0.000113	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.55e-05	0.000113	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.51e-05	0.000112	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.51e-05	0.000111	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.47e-05	0.00011	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.46e-05	0.000109	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.44e-05	0.000108	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.43e-05	0.000108	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.42e-05	0.000107	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.41e-05	0.000107	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.41e-05	0.000107	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.39e-05	0.000106	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.39e-05	0.000106	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2.34e-05	0.000104	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.32e-05	0.000103	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.31e-05	0.000103	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.29e-05	0.000102	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.27e-05	0.000101	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.25e-05	9.98e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.13e-05	9.46e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.11e-05	9.38e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.06e-05	9.13e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.91e-05	8.51e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.88e-05	8.34e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.8e-05	8.01e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.73e-05	7.67e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.71e-05	7.62e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.71e-05	7.61e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.67e-05	7.42e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.66e-05	7.37e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.64e-05	7.31e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.59e-05	7.08e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.59e-05	7.07e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	7e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	7e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.51e-05	6.7e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.48e-05	6.58e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.48e-05	6.56e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.39e-05	6.19e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.36e-05	6.04e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.35e-05	5.98e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.29e-05	5.72e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.23e-05	5.46e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.18e-05	5.26e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.17e-05	5.22e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.13e-05	5.02e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.13e-05	5.02e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.12e-05	4.98e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.08e-05	4.82e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.88e-06	3.95e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.74e-06	3.44e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.39e-06	3.28e-05	CbGpPWpGaD
